No Data
No Data
Tsumura To Go Ex-Dividend On September 27th, 2024 With 68 JPY Dividend Per Share
September 26th (Japan Standard Time) - $Tsumura(4540.JP)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 68 JPY dividend per share. The ex-
Stocks moved the previous day part1: Celes, Nippon Steel, Sakura Internet, etc.
Stock Name <Code> Closing Price on the 24th ⇒ Day Before Comparison Izawa Shou G <8708> 1844 +3325 The scheduled total dividend for the interim dividend for the fiscal year ending in March 2025 is ordinary dividend of 13 yen and special dividend of 35 yen. Keisan Sei <6742> 496 -1425 downward revision of performance forecast for the first half of the fiscal year ending in March 2025. VIS <130A> 1046 +89 Progress in joint drug discovery research with Shionogi <4507> leading to milestone achievement. Grandies <3261> 634 +100 Establishment of shareholder benefit system. QPS Research Institute <55
Nomura Starts Tsumura at Buy With 6,000 Yen Price Target
Wakamato, Sakura, Shimaseiki, etc.
Significant increase. At SMBC Nikko Securities, the investment rating has been upgraded from "2" to "1", and the target stock price has also been raised from 7000 yen to 8200 yen.
Volume change rate ranking (1:00 pm) - CyberTrust, 日本ビジネスシステム etc. are ranked.
In the volume change rate ranking, you can understand the market participants' interests, such as trends in investment, by comparing the average volume of the last 5 days with the volume on the day of delivery. ■ Volume Change Rate Top [As of 13:32 on September 24] (Comparison of the average volume of the last 5 days) Code⇒Stock⇒Volume⇒5-day average volume⇒Volume change ratio⇒Stock price change rate<2134> Kitahama Kapi 63551200 82980.26 322.34% 0.421%<7711> Asa
Tsumura - significant surge, domestic securities recommend buy as entering a trend of substantial performance growth.
Tsumura <4540> is sharply rising. Nomura Securities has newly rated it as a 'Buy', with a target stock price of 6,000 yen. With the significant drug price increase in the fiscal year ending March 2025, the growth track of traditional Chinese medicine prescriptions in Japan and the business in China are on a growth trajectory, indicating a full-fledged trend of performance growth. It seems that the Chinese government's policy of promoting the development and quality improvement of classic prescriptions is also providing favorable tailwinds. The medium-term revenue growth rate until the fiscal year ending March 2029 is 7.8% per year, and the operating profit is the same.
No Data
No Data